Tarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $776,500.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director William Phd Link sold 12,500 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the transaction, the director owned 106,786 shares in the company, valued at approximately $6,633,546.32. The trade was a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS traded up $1.75 during midday trading on Wednesday, hitting $62.55. The company’s stock had a trading volume of 462,278 shares, compared to its average volume of 606,366. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The firm’s fifty day moving average price is $63.62 and its 200-day moving average price is $69.67. The firm has a market cap of $2.69 billion, a P/E ratio of -54.87 and a beta of 0.49.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The firm had revenue of $162.05 million for the quarter, compared to analyst estimates of $149.60 million. On average, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TARS. Rockefeller Capital Management L.P. raised its stake in shares of Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares in the last quarter. Parallel Advisors LLC grew its position in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after buying an additional 291 shares in the last quarter. State of Wisconsin Investment Board grew its position in Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after buying an additional 332 shares in the last quarter. Federated Hermes Inc. increased its stake in Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after buying an additional 339 shares during the period. Finally, Valeo Financial Advisors LLC increased its stake in Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after buying an additional 392 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TARS shares. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Guggenheim upped their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.